-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR) Drug Details: Vorolanib is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Liposarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Liposarcoma Drug Details: ATX-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Colorectal Cancer Drug Details: ATX-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Solid Tumor Drug Details: ATX-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Leiomyosarcoma Drug Details: ATX-101 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATX-101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATX-101 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATX-101 in Non-Small Cell Lung Cancer Drug Details: ATX-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-91633 in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CC-91633 in Relapsed Acute Myeloid Leukemia Drug Details: CC-91633 (BMS-986397) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-819 in B-Cell Acute Lymphocytic...
-
Product Insights
Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Drugs In Development, 2023’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Progressive Multiple Sclerosis (PPMS) - Drugs In Development, 2023’, provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...